Skip to main content

Table 2 Baseline characteristics of the study cohorts after the propensity score matching

From: Comparative analysis of real-world data on the efficacy and safety of and adherence to ICS/LABA combinations in asthma management

 

Types subcohort

ICS subcohort

LABA subcohort

 

DPI

(n = 4525)

pMDI

(n = 4525)

P-value

Budesonide

(n = 3124)

Fluticasone

(n = 3124)

P-value

Formoterol

(n = 1459)

Salmeterol

(n = 1459)

P-value

Age (years)

49.0 ± 15.3

49.3 ± 15.2

0.495

47.7 ± 15.2

47.7 ± 15.5

0.989

50.9 ± 14.9

51.6 ± 15.1

0.187

Female (n,%)

1979 (43.7)

2006 (44.3)

0.567

1485 (47.5)

1506 (48.2)

0.594

563 (38.5)

589 (40.3)

0.324

Income

       

 Low

1259 (27.8)

1262 (27.8)

0.995

883 (28.2)

896 (28.6)

0.935

474 (32.4)

468 (32.0)

0.879

 Mid

1472 (32.5)

1468 (32.4)

 

1036 (33.1)

1031 (33.0)

 

493 (33.7)

486 (33.3)

 

 High

1794 (39.6)

1795 (39.6)

 

1205 (38.5)

1197 (38.3)

 

492 (33.7)

505 (34.6)

 

Region

       

 Urban

4172 (92.2)

4171 (92.1)

0.968

2904 (92.9)

2898 (92.7)

0.768

1350 (92.5)

1352 (92.6)

0.887

 Rural

353 (7.8)

354 (7.8)

 

220 (7.0)

226 (7.2)

 

109 (7.47)

107 (7.33)

 

Comorbidities

       

 Hypertensive disorder

1557 (34.4)

1557 (34.4)

1.00

948 (30.3)

953 (30.5)

0.890

553 (37.9)

570 (39.0)

0.517

 Diabetes mellitus

1476 (32.6)

1506 (33.2)

0.502

1007 (32.2)

999 (31.9)

0.828

503 (34.4)

523 (35.8)

0.438

 Hyperlipidemia

2523 (55.7)

2602 (57.5)

0.093

1701 (54.4)

1675 (53.6)

0.509

792 (54.2)

788 (54.0)

0.881

 Pneumonia

1915 (42.3)

1947 (43.0)

0.496

1294 (41.4)

1272 (40.7)

0.571

533 (36.5)

544 (37.2)

0.673

 Renal impairment

180 (3.9)

183 (4.0)

0.872

114 (3.6)

113 (3.6)

0.946

40 (2.7)

55 (3.7)

0.117

 Liver disease

2744 (60.6)

2790 (61.6)

0.321

1864 (59.6)

1873 (59.9)

0.816

897 (61.4)

890 (61.0)

0.790

 Acute respiratory disease

4437 (98.0)

4447 (98.2)

0.433

3070 (98.2)

3072 (98.3)

0.844

1419 (97.2)

1410 (96.6)

0.332

 Gastro-esophageal disease

3611 (79.8)

3618 (79.9)

0.854

2477 (79.2)

2497 (79.9)

0.530

1003 (68.7)

1031 (70.6)

0.259

 Urinary tract infection

584 (12.9)

598 (13.2)

0.662

419 (13.4)

394 (12.6)

0.347

168 (11.5)

174 (11.9)

0.729

 Rheumatoid arthritis

76 (1.6)

81 (1.7)

0.687

53 (1.7)

50 (1.6)

0.765

24 (1.6)

18 (1.2)

0.351

 Osteoarthritis

685 (15.1)

700 (15.4)

0.661

455 (14.5)

458 (14.6)

0.914

197 (13.5)

213 (14.6)

0.394

 Dementia

84 (1.8)

88 (1.9)

0.758

48 (1.5)

45 (1.4)

0.754

19 (1.3)

19 (1.3)

1.00

CCI scores

1.71 ± 1.11

1.72 ± 1.11

0.671

1.65 ± 1.05

1.66 ± 1.05

0.800

1.74 ± 1.12

1.77 ± 1.16

0.494

  1. CCI, Charlson Comorbidity Index; DPI, dry powder inhaler; ICS, inhaled corticosteroid; LABA, long-acting \(\:\beta\:\)2 agonist; MDI, metered dose inhaler